New drug cocktail aims to shrink liver tumors before surgery
NCT ID NCT05194293
First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether combining the targeted drug regorafenib with the immunotherapy durvalumab can shrink high-risk liver cancer before surgery. The study enrolled 4 adults with stage IB to IIIA hepatocellular carcinoma. Researchers are measuring how many patients see their tumors shrink and whether they can safely undergo surgery afterward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib and durvalumab
- What this could lead to
- If successful, this combination could shrink high-risk liver tumors before surgery, potentially improving outcomes for patients with advanced liver cancer.
- What could go wrong
- This is a very small, early-phase trial with only 4 participants. The treatment may not shrink tumors effectively, and side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IB HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- New drug zanzalintinib tested for advanced liver cancer
- Liver cancer drug trial halted after just 3 patients
- New combo therapy aims to shrink untreatable liver tumors
- Custom-Made cancer vaccine shows promise in advanced tumors
- Morning vs. afternoon: can timing boost cancer immunotherapy?